Onera Health, a Netherlands-based medical technology maker, has officially launched its sleep diagnostics solution dubbed Onera Polysomnography-as-a-Service to diagnose sleep disorders in Europe.
The company announced the launch of the solution in certain European markets at the International Congress 2022 of the European Respiratory Society (ERS).
The Onera Sleep Test System and the Onera Digital Health Platform, which are both CE-marked and cleared by the US Food and Drug Administration (FDA), are the foundation of the Onera Polysomnography-as-a-Service solution.
According to Onera Health, its sleep diagnostics solution enables sleep specialists to carry out sleep tests at patients’ houses while maintaining clinical-grade quality similar to in-lab diagnoses.
The Onera Polysomnography-as-a-Service will be available in The Netherlands and Germany from this year onwards, while the rollout in other European countries will be over the coming months.
Onera Health CEO and co-founder Ruben de Francisco said: “For many years, comprehensive sleep diagnostics was mainly possible in in-patient laboratories that required significant resources, resulting in long waiting times and often poor patient experience.
“Our innovative solution enables large scale utilisation of at-home polysomnography. This will not only increase patient comfort during a sleep study significantly, it will also improve access and shorten the diagnostic journeys of patients suffering from sleep disorders.”
Onera Health will exhibit the sleep diagnostics solution at the Fira Gran Via Convention Center Barcelona and share new results from current clinical validation studies around the Onera STS (Sleep Test System) during the 2022 ERS International Congress.
Onera Health chief medical officer and co-founder Hartmut Schneider said: “Sleep medicine struggled to keep up with the increasing prevalence of sleeping disorders for too long.
“Onera’s Polysomnography-as-a-Service solution allows to end delays in diagnosis, while at the same time ensuring a high-level of signal quality unseen in at-home sleep testing.
“This is especially important for patients with advanced or complicated sleep disorders.”
